Ambigon Therapeutics

Ambagon Therapeutics is a private, preclinical biotechnology company developing small-molecule molecular glues that stabilize interactions between 14-3-3 adaptor proteins and disease-relevant client proteins. Its platform is designed to drug intrinsically disordered and other historically hard-to-target proteins, with an initial emphasis on oncology and emerging interest in neurodegenerative disease biology. The company was founded in 2020 by scientific leaders in 14-3-3 biology from Eindhoven University of Technology and UCSF and launched publicly in 2022 with an $85 million Series A financing. Ambagon operates across the United States and the Netherlands and positions itself as a platform company capable of generating multiple first-in-class programs against previously undruggable targets.